Drugs & Therapy Perspectives

McKeage, Kate; Lyseng-Williamson, Katherine

doi: 10.1007/s40267-018-0540-0pmid: N/A

Hialid®/Hyalein® (also known as Sanlein®) is an effective and well tolerated ophthalmic solution for the treatment of keratoconjunctival epithelial disorder associated with dry eye syndrome. Hialid®/Hyalein® contains the active ingredient sodium hyaluronate, a natural component of tear film, which has high water retention ability, increases tear film stability and accelerates corneal wound healing. One drop in each eye 5–6 times daily improves the symptoms of dry eye, as well as objective measures of corneal staining. The efficacy of the solution is noninferior to that of ciclosporin 0.05% anionic emulsion eye drops in this patient population.

Lyseng-Williamson, Katherine

doi: 10.1007/s40267-018-0539-6pmid: N/A

Amphetamine extended-release oral suspension (Adzenys ER™) and extended-release orally disintegrating tablets (Adzenys XR-ODT®) are easy-to-administer, long-acting, and convenient CNS stimulant options for treating attention-deficit hyperactivity disorder (ADHD) in children aged ≥ 6 years, adolescents, and adults. The bioavailability of d- and l-amphetamine with Adzenys ER™ suspension and XR-ODT® is equivalent to that of a corresponding dose of the reference product [i.e. mixed amphetamine salt extended-release capsules (MAS ER)], which has well-established efficacy, tolerability, and safety profiles. As Adzenys ER™ suspension/XR-ODT® contain both immediate- and extended-release amphetamine particles, plasma concentrations of d- and l-amphetamine increase rapidly, remain relatively stable for several hours, then slowly decline, allowing for once-daily administration. The use of Adzenys ER™ suspension/XR-ODT® may be of particular benefit in individuals who require a rapid onset and prolonged reduction in ADHD symptoms, as well as those who have difficulty swallowing tablets or capsules whole (neither formulation requires swallowing whole tablets/capsules, and both may be taken without regard to food).

Writers, Adis

doi: 10.1007/s40267-018-0545-8pmid: N/A

Flushing and gastrointestinal effects are most common adverse effects associated with the use of oral delayed-release dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis. While these adverse effects are usually transient and mild to moderate in severity, strategies to prevent and manage symptoms can help avoid treatment cessation. Management strategies should be individualized and patients given ongoing support.

Adis Medical Writers;

doi: 10.1007/s40267-018-0533-zpmid: N/A

Tattoos are becoming increasingly common and are the result of a variety of underlying motivations. Patients with medical or skin conditions should be advised of the tattooing-related risks and recommendations specific for their condition. Tattooing is strictly contraindicated in only a few medical/skin conditions (i.e. pregnancy, breastfeeding, severe immunosuppression, tumour-related scars). In other medical/skin conditions, tattoo-related risks should be considered and recommendations and precautions followed.

Phan, Stephanie

doi: 10.1007/s40267-018-0523-1pmid: N/A

Hasan, Syed; Liew, Annita; Chong, David; Thiruchelvam, Kaeshaelya; Babar, Zaheer-Ud-Din

doi: 10.1007/s40267-018-0521-3pmid: N/A

Irungu, K.; Nyamu, D.; Opanga, S.

doi: 10.1007/s40267-018-0512-4pmid: N/A